https://orcid.org/0000-0002-7317-965X
Figures & data
Table 1. The clinical characteristics of patients.
Table 2. Primer sequences.
Figure 1. MALAT1 and CXCR4 are upregulated while miR-146a is downregulated in AML patients. The expression of MALAT1 (A), miR-146a (B) and CXCR4 (C) were measured in PBMSCs cells from AML patients (n = 20) or normal controls (n = 20) by qRT-PCR. The Spearman's correlation analyses were performed to analyze the correlation between MALAT1 and miR-146a (D), the correlation between CXCR4 and miR-146a (E), the correlation between MALAT1 and CXCR4 (F). *P < 0.05, **P < 0.01.
Figure 2. Effects of MALAT1 knockdown on migration, proliferation and apoptosis of HL-60 cells. HL-60 cells were transfected with si-NC or si-MALAT1 for 48h, then the transfection efficiency was evaluated by qRT-PCR (A). (B) Tran-swell assay was implemented to analyze cell migration at 48h in H-60 cells transfected with si-NC or si-MALAT1. (C) CCK-8 assay was performed to measure cell proliferation at 0, 24, 48 and 72h in H-60 cells transfected with si-NC or si-MALAT1. (D) Flow cytometry was conducted to determine cell apoptosis at 48h in HL-60 cells transfected with si-NC or si-MALAT1. Control: non-transfected group. *P < 0.05, **P < 0.01, *** P < 0.001.
Figure 3. The interaction between MALAT1 and miR-146a in HL-60 cells. (A) The potential binding sites of MALAT1 and miR-146a were predicted by StarBase website. (B) Luciferase activity was measured by luciferase reporter assay 48h after HL-60 cells were transfected with MALAT1-WT or MALAT1-MUT and miR-146a mimic or mi-NC. (C) The expression of miR-146a was detected in HL-60 cells transfected with si-NC or si-MALAT1 for 48h by qRT-PCR. Control: non-transfected group. (D) The expression of MALAT1 was measured in HL-60 cells transfected with mi-NC, miR-146a mimic or miR-146a inhibitor for 48h by qRT-PCR. Control: non-transfected group. *P < 0.05, **P < 0.01.
Figure 4. The interaction between miR-146a and CXCR4 in HL-60 cells. mi-NC, miR-146a mimic or miR-146a inhibitor was transfected into HL-60 cells to achieve miR-146a overexpression or inhibition. The transfection efficiency was measured by qRT-PCR (A). The expression of CXCR4 mRNA (B) and protein (C) were evaluated in HL-60 cells transfected with mi-NC, miR-146a mimic or miR-146a inhibitor at 48h by qRT-PCR and Western Blot assays. Control: non-transfected group. (D) The potential binding sites of CXCR4 and miR-146a. (E) Luciferase activity was measured by luciferase reporter assay 48h after HL-60 cells were transfected with CXCR4-WT or CXCR4-MUT and miR-146a mimic or mi-NC. *P < 0.05, **P < 0.01, *** P < 0.001.
Figure 5. miR-146a regulates migration, proliferation and apoptosis in HL-60 cells. mi-NC, miR-146a mimic or miR-146a inhibitor was transfected into HL-60 cells to achieve miR-146a overexpression or inhibition. (A) Tran-swell assay was implemented to analyze cell migration at 48h in H-60 cells transfected with mi-NC, miR-146a mimic or miR-146a inhibitor. (B) CCK-8 assay was performed to measure cell proliferation at 0, 24, 48 and 72h in H-60 cells transfected with mi-NC, miR-146a mimic or miR-146a inhibitor. (C) Flow cytometry was conducted to determine cell apoptosis at 48h in HL-60 cells transfected with mi-NC, miR-146a mimic or miR-146a inhibitor. Control: non-transfected group. *P < 0.05, **P < 0.01, *** P < 0.001.
Figure 6. MALAT1 regulates CXCR4 expression through miR-146a. HL-60 cells were co-transfected with si-NC/si-MALAT1 and mi-NC/mi-R146a inhibitor for 48h. Then CXCR4 mRNA (A) and protein (B) were measured by qRT-PCR and Western Blot assay, respectively. Control: non-transfected group. *P < 0.05, **P < 0.01, *** P < 0.001.
